{"altmetric_id":18943227,"selected_quotes":["#Atezolizumab gets @US_FDA accelerated approval as first line treatment for cisplatin-ineligible bladder cancer","A late setback for atezolizumab to treat bladder cancer, only a month after"],"citation":{"altmetric_jid":"ecancerorg","first_seen_on":"2017-04-18T12:00:37+00:00","issns":[],"journal":"ecancer","last_mentioned_on":1494428510,"links":["http:\/\/ecancer.org\/news\/11458-fda-grants-atezolizumab-accelerated-approval-as-initial-treatment-for-certain-advanced-bladder-cancer-cases.php"],"title":"FDA grants atezolizumab accelerated approval as initial treatment for certain advanced bladder cancer cases","type":"news","uri":"http:\/\/ecancer.org\/news\/11458-fda-grants-atezolizumab-accelerated-approval-as-initial-treatment-for-certain-advanced-bladder-cancer-cases.php"},"altmetric_score":{"score":2.1,"score_history":{"1y":2.1,"6m":2.1,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":2.1},"context_for_score":{"all":{"total_number_of_other_articles":8183187,"mean":6.9217013823156,"rank":3492009,"this_scored_higher_than_pct":56,"this_scored_higher_than":4655445,"rank_type":"exact","sample_size":8183187,"percentile":56},"similar_age_3m":{"total_number_of_other_articles":237893,"mean":12.836349662872,"rank":96587,"this_scored_higher_than_pct":58,"this_scored_higher_than":139287,"rank_type":"exact","sample_size":237893,"percentile":58},"this_journal":{"total_number_of_other_articles":11848,"mean":2.8803688697561,"rank":3838,"this_scored_higher_than_pct":65,"this_scored_higher_than":7767,"rank_type":"exact","sample_size":11848,"percentile":65},"similar_age_this_journal_3m":{"total_number_of_other_articles":1,"mean":0,"rank":1,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":1,"percentile":1}}},"demographics":{"poster_types":{"member_of_the_public":3,"practitioner":1,"science_communicator":1},"users":{"twitter":{"cohorts":{"Practitioners (doctors, other healthcare professionals)":1,"Science communicators (journalists, bloggers, editors)":1,"Members of the public":3}}},"geo":{"twitter":{"GB":2,"AU":1}}},"counts":{"total":{"posts_count":6},"twitter":{"unique_users_count":5,"unique_users":["ecancer","RichMedicine","CancerWallonia","MartinStockler","hlthnews"],"posts_count":6}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/ecancer\/statuses\/854303597785436163","license":"gnip","citation_ids":[18943227],"posted_on":"2017-04-18T12:00:24+00:00","author":{"name":"ecancer","url":"http:\/\/www.ecancer.org","image":"https:\/\/pbs.twimg.com\/profile_images\/449503716438056960\/SqsDdkL0_normal.png","description":"ecancer is a not for profit, open access, independent medical education platform, committed to improving cancer communication & education.","id_on_source":"ecancer","tweeter_id":"19975787","geo":{"lt":52.16045,"ln":-0.70312,"country":"GB"},"followers":12891},"tweet_id":"854303597785436163"},{"url":"http:\/\/twitter.com\/RichMedicine\/statuses\/854308749737152514","license":"gnip","rt":["ecancer"],"citation_ids":[18943227],"posted_on":"2017-04-18T12:20:52+00:00","author":{"name":"Richard Greensmith","image":"https:\/\/pbs.twimg.com\/profile_images\/766371864222527489\/CO3cYGWf_normal.jpg","description":"Bladder Cancer PhD  | Scientific Editor & Consultant I GEM applicant","id_on_source":"RichMedicine","tweeter_id":"766354891556126720","geo":{"lt":53.41058,"ln":-2.97794,"country":"GB"},"followers":22},"tweet_id":"854308749737152514"},{"url":"http:\/\/twitter.com\/CancerWallonia\/statuses\/854313211428032512","license":"gnip","rt":["ecancer"],"citation_ids":[18943227],"posted_on":"2017-04-18T12:38:36+00:00","author":{"name":"CancerWallonia","image":"https:\/\/pbs.twimg.com\/profile_images\/623178120615604224\/unGEOij0_normal.jpg","description":"Cancer: from Wallonia to the World, from the World to Wallonia -  Cancer: la Wallonie parle au Monde, le Monde parle \u00e0 la Wallonie","id_on_source":"CancerWallonia","tweeter_id":"2848852120","geo":{"lt":null,"ln":null},"followers":600},"tweet_id":"854313211428032512"},{"url":"http:\/\/twitter.com\/MartinStockler\/statuses\/854441095949729792","license":"gnip","rt":["ecancer"],"citation_ids":[18943227],"posted_on":"2017-04-18T21:06:46+00:00","author":{"name":"Martin Stockler","url":"http:\/\/sydney.edu.au\/medicine\/people\/academics\/profiles\/martin.stockler.php","image":"https:\/\/pbs.twimg.com\/profile_images\/874086499217588224\/igNEgYOC_normal.jpg","description":"Grappling with oncology, clinical research, quality of life, prognostication, communication, education, rabbitohs, wallabies, crickets, and other enigmas","id_on_source":"MartinStockler","tweeter_id":"177787568","geo":{"lt":-33.86785,"ln":151.20732,"country":"AU"},"followers":1095},"tweet_id":"854441095949729792"},{"url":"http:\/\/twitter.com\/hlthnews\/statuses\/854923408626286593","license":"gnip","citation_ids":[18943227],"posted_on":"2017-04-20T05:03:18+00:00","author":{"name":"Hlthnews","image":"https:\/\/pbs.twimg.com\/profile_images\/828610774411063296\/6EetzB7Z_normal.jpg","description":"Your best source for health related news","id_on_source":"hlthnews","tweeter_id":"160870443","geo":{"lt":null,"ln":null},"followers":477},"tweet_id":"854923408626286593"},{"url":"http:\/\/twitter.com\/ecancer\/statuses\/862321791209013248","license":"gnip","citation_ids":[18943227],"posted_on":"2017-05-10T15:01:50+00:00","author":{"name":"ecancer","url":"http:\/\/www.ecancer.org","image":"https:\/\/pbs.twimg.com\/profile_images\/449503716438056960\/SqsDdkL0_normal.png","description":"ecancer is a not for profit, open access, independent medical education platform, committed to improving cancer communication & education.","id_on_source":"ecancer","tweeter_id":"19975787","geo":{"lt":52.16045,"ln":-0.70312,"country":"GB"},"followers":12891},"tweet_id":"862321791209013248"}]}}